Pralsetinib also received accelerated approval from the FDA (4 September 2020) for the treatment of metastatic RET fusion–positive NSCLC and was granted conditional marketing authorization by the EMA (18 November 2021) [22]. This evidence concerns the gene RET and non-small cell lung carcinoma.